^
Association details:
| Biomarker: | CDKN2A deletion |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + JQ-1 (BET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract PO-122: Combined CDK and BET inhibition reprograms the tumor and stromal compartments to enhance anti-tumor immunity in immunologically-cold CDKN2A-deficient pancreatic cancer
Published date:
11/15/2021
Excerpt:
Loss of CDKN2A rendered KPC-luc cells susceptible to direct apoptosis from dual CDK/BET inhibition….In vivo, combined BET/CDK inhibition increased T cell infiltration into PDAC tumors, and when combined with PD-L1 blockade diminished tumor growth….This suggests combined CDK/BET inhibition may be a personalized therapeutic approach for patients with CKDN2A-deficient PDAC, and a means to sensitize PDAC to immunotherapy.
DOI:
https://doi.org/10.1158/1538-7445.PANCA21-PO-122
